Advertisements


Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

Category: topSource: foxnewsApr 16th, 2018

Shire sells cancer drugs to Servier as Takeda circles

Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceu.....»»

Category: videoSource: reutersApr 16th, 2018

Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

Category: topSource: foxnewsApr 16th, 2018

Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles

LONDON (Reuters) - Shire , the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical , is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion......»»

Category: topSource: reutersApr 16th, 2018

Shire Sells Oncology Unit Ahead of Takeda"s Potential Offer

Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. T.....»»

Category: smallbizSource: nytApr 17th, 2018

Takeda clears key hurdle as investors back $59 billion Shire deal

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire , creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt......»»

Category: topSource: reutersDec 5th, 2018

$59bln: What it costs to become a drugs player

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Julian Satterthwaite reports......»»

Category: videoSource: reutersDec 5th, 2018

Takeda investors back $59 billion Shire deal, but wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Category: topSource: reutersDec 5th, 2018

Takeda shareholders give nod for $59 billion Shire acquisition

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Category: topSource: reutersDec 4th, 2018

Takeda shareholders approve Shire acquisition: spokesman

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , a Takeda spokesman said, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Category: topSource: reutersDec 4th, 2018

Japan"s Takeda clinches $62 billion Shire deal as pharma M&A rolls on

LONDON/TOKYO (Reuters) - Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry......»»

Category: topSource: reutersMay 8th, 2018

Japan"s Takeda sweetens $62 billion Shire offer

TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals......»»

Category: topSource: reutersApr 20th, 2018

Shire to Sell Oncology Unit as Takeda Mulls Takeover

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Category: smallbizSource: wsjApr 16th, 2018

Shire to Sell Oncology Unit for $2.4 Billion as Takeda Mulls Takeover

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Category: smallbizSource: wsjApr 16th, 2018

Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

Zacks.....»»

Category: topSource: redinewsDec 14th, 2018

Shire downgraded to Hold at SunTrust on Takeda merger

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 12th, 2018

How a tiny seaweed-dwelling animal led this East Bay startup to HIV, cancer

The synthetic sibling of an expensive molecule harvested from a tiny seaweed-dwelling animal could lead to next-generation cancer drugs or a functional cure for HIV, an East Bay company believes. Those lofty targets are years in the distance for s.....»»

Category: topSource: bizjournalsDec 11th, 2018

Abrams Capital Management Buys Shire PLC, Lithia Motors Inc, Franklin Resources Inc, Sells ...

Related Stocks: LAD, BEN, ESRX, ABG, SHPG, CWH, AKBA, PCG, QCP, GPI,.....»»

Category: dealsSource: nytDec 7th, 2018

Takeda aims to fix balance sheet within 5 years of Shire purchase, Nikkei says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 6th, 2018

Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies. Shire Plc. SHPG announced that its acquisition .....»»

Category: worldSource: nytDec 6th, 2018

Takeda Shareholders Approve Shire Megadeal

Buying Shire in a merger valued at $58 billion today would enable Takeda to tap into the lucrative market for rare diseases and boosts the CEO’s mission to expand Takeda’s footprint beyond its slowing home market......»»

Category: asiaSource: wsjDec 6th, 2018